Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of cancer risk to help physicians proactively manage patient health. The Company's lead products, 'GeneType for Breast Cancer' and 'GeneType for Colorectal Cancer', are clinically validated risk assessment tests that are first in their class. The Company's development pipeline includes new tests for Type 2 diabetes, cardiovascular disease, prostate cancer, and melanoma. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
A live Q&A session, open to current and prospective investors, will immediately follow Interim-CEO Dr. George Muchnicki's presentation.
For more information on Genetic Technologies (NASDAQ: GENE), visit http://www.genetechinfo.com
View investor deck